Extra cycles of neoadjuvant chemotherapy before interval surgery for ovarian cancer: the more the merrier or too much of a good thing?
作者信息
Nitecki Roni, Melamed Alexander
机构信息
Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
出版信息
Int J Gynecol Cancer. 2022 Aug 1;32(8):975-976. doi: 10.1136/ijgc-2022-003796.
Abstract
摘要
相似文献
1
Extra cycles of neoadjuvant chemotherapy before interval surgery for ovarian cancer: the more the merrier or too much of a good thing?卵巢癌间隔手术前新辅助化疗周期增加：越多越好还是过犹不及？
Int J Gynecol Cancer. 2022 Aug 1;32(8):975-976. doi: 10.1136/ijgc-2022-003796.
2
Interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer - retrospective study comparing surgery after 3 cycles or more of chemotherapy.新辅助化疗后晚期卵巢癌的间隔减瘤手术 - 比较化疗 3 个周期及以上后手术的回顾性研究。
J Gynecol Obstet Hum Reprod. 2022 Sep;51(7):102409. doi: 10.1016/j.jogoh.2022.102409. Epub 2022 May 14.
3
Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.新辅助化疗后延迟细胞减灭术治疗晚期上皮性卵巢癌的生存结局。
Int J Gynecol Cancer. 2020 Dec;30(12):1935-1942. doi: 10.1136/ijgc-2020-001658. Epub 2020 Oct 29.
4
Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.晚期上皮性卵巢癌的术后残留病灶和新辅助化疗周期数。
Int J Gynecol Cancer. 2023 Aug 7;33(8):1270-1278. doi: 10.1136/ijgc-2022-004249.
5
Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.接受新辅助治疗和中间性细胞减灭术后接受三个周期与更多周期化疗的卵巢癌患者的临床结局。
Int J Gynecol Cancer. 2019 Sep;29(7):1156-1163. doi: 10.1136/ijgc-2019-000374. Epub 2019 Jul 27.
6
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.CHRONO：新辅助化疗后卵巢癌手术时间的随机临床试验。
Int J Gynecol Cancer. 2022 Aug 1;32(8):1071-1075. doi: 10.1136/ijgc-2021-003320.
7
Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.GEICO 1205 研究的疗效和安全性结果，这是一项针对晚期上皮性卵巢癌新辅助化疗加或不加贝伐珠单抗的随机 II 期临床试验。
Int J Gynecol Cancer. 2019 Jul;29(6):1050-1056. doi: 10.1136/ijgc-2019-000256.
8
3-4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles.3-4 个周期与 6 个周期新辅助化疗治疗晚期上皮性卵巢癌：生存并非由新辅助化疗周期数决定。
Chemotherapy. 2024;69(2):122-132. doi: 10.1159/000535755. Epub 2023 Dec 19.
9
To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.比较 3 个与 6 个疗程新辅助化疗后 III/IV 期上皮性卵巢癌的最佳减瘤率。
J Obstet Gynaecol. 2021 May;41(4):616-620. doi: 10.1080/01443615.2020.1787967. Epub 2020 Aug 19.
10
Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.比较尼拉帕利与铂类紫杉类联合化疗作为新诊断同源重组缺陷型 III/IV 期卵巢癌患者的新辅助治疗：开放标签、2 期、随机对照、多中心 OPAL 试验队列 C 的研究方案。
Trials. 2024 May 4;25(1):301. doi: 10.1186/s13063-024-08142-5.
本文引用的文献
1
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer.晚期卵巢癌患者中，根据新辅助化疗周期数，组织学反应对生存的影响
Int J Gynecol Cancer. 2022 Aug 1;32(8):967-974. doi: 10.1136/ijgc-2021-003313.
2
CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.CHRONO：新辅助化疗后卵巢癌手术时间的随机临床试验。
Int J Gynecol Cancer. 2022 Aug 1;32(8):1071-1075. doi: 10.1136/ijgc-2021-003320.
3
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.晚期卵巢上皮癌初始治疗中化疗与手术的比较
Cochrane Database Syst Rev. 2019 Oct 31;2019(10):CD005343. doi: 10.1002/14651858.CD005343.pub4.
4
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.新诊断晚期卵巢癌的新辅助化疗：妇科肿瘤学会和美国临床肿瘤学会临床实践指南
J Clin Oncol. 2016 Oct 1;34(28):3460-73. doi: 10.1200/JCO.2016.68.6907. Epub 2016 Aug 8.
5
Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?晚期卵巢癌中间隔肿瘤减灭术的最佳时机：尚未确定？
Eur J Obstet Gynecol Reprod Biol. 2011 Dec;159(2):407-12. doi: 10.1016/j.ejogrb.2011.07.014. Epub 2011 Aug 10.
6
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis.铂类新辅助化疗及间隔期手术细胞减灭术治疗晚期卵巢癌的荟萃分析
Gynecol Oncol. 2006 Dec;103(3):1070-6. doi: 10.1016/j.ygyno.2006.06.025. Epub 2006 Jul 27.
Zotero 插件